Ключевые слова
Как цитировать
Аннотация
Введение. Международным профессиональным сообществом созданы специализированные программы менеджмента, рекомендации и инструкции, разработанные для медицинских работников и пациентов, принимающих пероральные формы противоопухолевых лекарственных препаратов (ПОЛП). Однако в русскоязычном сегменте исследований и научной литературы имеется ограниченное количество фрагментарных данных по безопасной практике применения пероральных ПОЛП.
Цель. Обозначить ключевые аспекты безопасности терапии пероральными ПОЛП, а также привести перечень рекомендаций по безопасному применению, предназначенных для использования как пациентами, так и медицинскими работниками. Авторы рекомендуют к использованию структурированные рекомендации The MASCC Oral Agent Teaching Tool (MOATT) ассоциации Multinational Association of Supportive Care in Cancer (MASCC) и адаптированные для самостоятельного применения пациентом рекомендации «Oral Chemotherapy Education» ассоциации The National Community Oncology Dispensing Association (NCODA). Авторами данной статьи осуществлен перевод и адаптация рекомендаций MASCC, которые доступны на официальном сайте ассоциации на русском языке для практического применения и проведения дальнейших исследований.
Библиографические ссылки
Komatsu H., Yagasaki K., Yamaguchi T. Effects of a nurse-led medication self-management programme in cancer patients: protocol for a mixed-method randomised controlled trial. BMC Nurs. 2016; 15: 9.-DOI: https://doi.org/10.1186/s12912-016-0130-1.
Peng Q., Wu W. Development and validation of oral chemotherapy self-management scale. BMC Cancer. 2020; 20: 890.-DOI: https://doi.org/10.1186/s12885-020-07404-0.
Aisner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Heal Pharm AJHP Off J Am Soc Heal Pharm. 2007; 64: S4-7.-DOI: https://doi.org/10.2146/ajhp070035.
Cuba L., Schlichtig K., Dürr P., et al. Optimizing medication safety with oral antitumor therapy: a methodological approach for the real-world implementation of the AMBORA competence and consultation center. Healthc (Basel, Switzerland). 2023; 11.-DOI: https://doi.org/10.3390/healthcare11111640.
Deluche E., Darbas T., Bourcier K., et al. Prospective evaluation of an anti-cancer drugs management programme in a dedicated oral therapy center (DICTO programme). Med Oncol. 2020; 37: 69.-DOI: https://doi.org/10.1007/s12032-020-01393-7.
Santaballa A., De Castro J., Maurel J., et al. Optimization of oral chemotherapy in outpatient clinics in Spain: results from a survey of the Spanish Society of Medical Oncology (SEOM). Clin Transl Oncol Off Publ Fed Spanish Oncol Soc Natl Cancer Inst Mex. 2019; 21: 534-8.-DOI: https://doi.org/10.1007/s12094-018-1951-z.
Gervès-Pinquié C., Daumas-Yatim F., Lalloué B., et al. Impacts of a navigation program based on health information technology for patients receiving oral anticancer therapy: the CAPRI randomized controlled trial. BMC Health Serv Res. 2017; 17: 133.-DOI: https://doi.org/10.1186/s12913-017-2066-x.
Mir O., Ferrua M., Fourcade A., et al. Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial. Nat Med. 2022.-DOI: https://doi.org/10.1038/s41591-022-01788-1.
Sivakumaran K., Ginex P.K., Waseem H., et al. Domains of structured oral anticancer medication programs: a scoping review. Oncol Nurs Forum. 2022; 49: 296-306.-DOI: https://doi.org/10.1188/22.ONF.296-306.
Schlichtig K., Dürr P., Dörje F., et al. New oral anti-cancer drugs and medication safety. Dtsch Arztebl Int. 2019; 116: 775-82.-DOI: https://doi.org/10.3238/arztebl.2019.0775.
Oakley C., Lennan E., Roe H., et al. Safe practice and nursing care of patients receiving oral anti-cancer medicines: a position statement from UKONS. Ecancermedicalscience. 2010; 4: 177.-DOI: https://doi.org/10.3332/ecancer.2010.177.
Belcher S.M., Mackler E., Muluneh B., et al. ONS GuidelinesTM to support patient adherence to oral anticancer medications. Oncol Nurs Forum. 2022; 49: 279-95.-DOI: https://doi.org/10.1188/22.ONF.279-295.
Mackler E., Segal E.M., Muluneh B., et al. 2018 Hematology/Oncology Pharmacist Association best practices for the management of oral oncolytic therapy: pharmacy practice standard. J Oncol Pract. 2019; 15: e346-55.-DOI: https://doi.org/10.1200/JOP.18.00581.
Neuss M.N., Gilmore T.R., Belderson K.M., et al. 2016 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards, including standards for pediatric oncology. J Oncol Pract. 2016; 12: 1262-71.-DOI: https://doi.org/10.1200/JOP.2016.017905.
Willemsen A.E., Lubberman F.J.E., Tol J., et al. Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors. Drug Discov Today. 2016; 21: 962-76.-DOI: https://doi.org/10.1016/j.drudis.2016.03.002.
Koch K.M., Reddy N.J., Cohen R.B., et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol Off J Am Soc Clin Oncol. 2009; 27: 1191-6.-DOI: https://doi.org/10.1200/JCO.2008.18.3285.
Koziolek M., Alcaro S., Augustijns P., et al. The mechanisms of pharmacokinetic food-drug interactions – A perspective from the UNGAP group. Eur J Pharm Sci. 2019; 134: 31-59.-DOI: https://doi.org/10.1016/j.ejps.2019.04.003.
Gampenrieder Satory J. Pharmacokinetic drug interactions of oral anticancer drugs. Memo - Mag Eur Med Oncol. 2022; 15: 298-302.-DOI: https://doi.org/10.1007/s12254-022-00849-y.
McQuade B.M., Campbell A. Drug prescribing: drug-drug interactions. FP Essent. 2021; 508: 25-32.
Wang H., Shi H., Wang Y., et al. Potentially hazardous drug-drug interactions associated with oral antineoplastic agents prescribed in chinese tertiary care teaching hospital settings: a multicenter cross-sectional study. Front Pharmacol. 2022; 13: 808848.-DOI: https://doi.org/10.3389/fphar.2022.808848.
Prely H., Herledan C., Caffin A.G., et al. Real-life drug–drug and herb–drug interactions in outpatients taking oral anticancer drugs: comparison with databases. J Cancer Res Clin Oncol. 2022; 148: 707-18.-DOI: https://doi.org/10.1007/s00432-021-03645-z.
Rogala B.G., Charpentier M.M., Nguyen M.K., et al. Oral anticancer therapy: management of drug interactions. J Oncol Pract. 2019; 15: 81-90.-DOI: https://doi.org/10.1200/JOP.18.00483.
Eisenmann E.D., Talebi Z., Sparreboom A., Baker S.D. Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions. Basic Clin Pharmacol Toxicol. 2022; 130 Suppl: 23-35.-DOI: https://doi.org/10.1111/bcpt.13623.
Shaherose S., Katta Charu G., Santa A., et al. 159MO Low-dose abiraterone with fatty food versus standard dose abiraterone in metastatic castration-resistant prostate cancer. Ann Oncol. 2022; 33: S1496.-DOI: https://doi.org/10.1016/j.annonc.2022.10.196.
Westra N., Touw D., Lub-de Hooge M., et al. Pharmacokinetic boosting of kinase inhibitors. Pharmaceutics. 2023; 15.-DOI: https://doi.org/10.3390/pharmaceutics15041149.
American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023; 71: 2052-81.-DOI: https://doi.org/10.1111/jgs.18372.
Farrell B., Conklin J., Dolovich L., et al. Deprescribing guidelines: An international symposium on development, implementation, research and health professional education. Res Social Adm Pharm. 2019; 15: 780-9.-DOI: https://doi.org/10.1016/j.sapharm.2018.08.010.
Schwaederle M., Zhao M., Lee J.J., et al. Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials. J Clin Oncol Off J Am Soc Clin Oncol. 2015; 33: 3817-25.-DOI: https://doi.org/10.1200/JCO.2015.61.5997.
Du R., Wang X., Ma L., et al. Adverse reactions of targeted therapy in cancer patients: a retrospective study of hospital medical data in China. BMC Cancer. 2021; 21: 206.-DOI: https://doi.org/10.1186/s12885-021-07946-x.
Kawasumi K., Kujirai A., Matsui R., et al. Survey of serious adverse events and safety evaluation of oral anticancer drug treatment in Japan: A retrospective study. Mol Clin Oncol. 2021; 14: 12.-DOI: https://doi.org/10.3892/mco.2020.2174.
Lasala R., Santoleri F., Romagnoli A., et al. Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe. Eur J Clin Pharmacol. 2019; 75: 697-706.-DOI: https://doi.org/10.1007/s00228-018-02621-w.
Ackland S.P., Michael M., de Souza P., et al. Science and art of anticancer drug dosing: nine steps to personalised therapy. Intern Med J. 2020; 50: 992-6.-DOI: https://doi.org/10.1111/imj.14948.
Fourie Zirkelbach J., Shah M., Vallejo J., et al. Improving dose-optimization processes used in oncology drug development to minimize toxicity and maximize benefit to patients. J Clin Oncol Off J Am Soc Clin Oncol. 2022; 40: 3489-500.-DOI: https://doi.org/10.1200/JCO.22.00371.
Algethami A.A., Alshamrani M.A., AlHarbi A.M., et al. Evaluation of handling, storage, and disposal practices of oral anticancer medications among cancer patients and their caregivers at home setting in the Princess Noorah Oncology Center. J Oncol Pharm Pract. 2020; 27: 20-5.-DOI: https://doi.org/10.1177/1078155220908937.
Hassan M.M., Al-Marzooq D., Al-Habsi H., et al. Patients’ knowledge and awareness of safe handling of oral anticancer agents at Sultan Qaboos University Hospital in Oman. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract. 2023; 29: 112-8.-DOI: https://doi.org/10.1177/10781552211056238.
Huff C. Oral Chemotherapy: A home safety educational framework for healthcare providers, patients, and caregivers. Clin J Oncol Nurs. 2020; 24: 22-30.-DOI: https://doi.org/10.1188/20.CJON.22-30.
Multinational Association of Supportive Care in Cancer (MASCC). MASCC Oral Agent Teaching Tool (MOATT). English. 2021.-URL: https://mascc.org/resources/assessment-tools/mascc-oral-agent-teaching-tool-moatt/.
The National Community Oncology Dispensing Association (NCODA). Oral Chemotherapy Education, OCE. 2023.-URL: https://www.oralchemoedsheets.com/sheets/Safe-Handling-Of-Oral-Chemo_Supplemental_Patient_Education.pdf.
American Society of Clinical Oncology (ASCO). ASCO answers. Oral Chemotherapy. 2021.-URL: https://www.cancer.net/sites/cancer.net/files/asco_answers_oral_chemotherapy.pdf.
The Association of Community Cancer Centers (ACCC). Oral chemotherapy– what your patients need to know. 2014.-URL: https://www.accc-cancer.org/docs/documents/oncology-issues/articles/2003-2016/2014/nd14/nd14-oral-chemotherapy-what-your-patients-need-to-know.pdf?sfvrsn=ce01f7e1_7.
Oncology Nursing Society (ONS). Oral Anticancer Medication Toolkit. 2022.-URL: https://www.ons.org/sites/default/files/2023-05/23%20OAM%20toolkit.pdf.
Goldspiel B., Hoffman J.M., Griffith N.L., et al. ASHP guidelines on preventing medication errors with chemotherapy and biotherapy. Am J Heal Pharm AJHP Off J Am Soc Heal Pharm. 2015; 72: e6-35.-DOI: https://doi.org/10.2146/sp150001.
Weingart S.N., Brown E., Bach P.B., et al. NCCN task force report: oral chemotherapy. J Natl Compr Canc Netw. 2008; 6 Suppl 3: S1-14.
Vu K., Emberley P., Brown E., et al. Recommendations for the safe use and handling of oral anticancer drugs in community pharmacy: A pan-Canadian consensus guideline. Can Pharm J (Ott). 2018; 151: 240-53.-DOI: https://doi.org/10.1177/1715163518767942.
Oral Chemotherapy Fact Sheet. Dana-Farber Cancer Institute. 2022; 3.-URL: https://www.dana-farber.org/uploadedFiles/oral-chemotherapy-safety-sheet.pdf.
How to Safely Handle Oral Chemotherapy. Memorial Sloan Kettering Cancer Center. 2024.-URL: https://www.mskcc.org/cancer-care/patient-education/how-safely-handle-oral-chemotherapy.
Chemotherapy at home: 9 things to know. The University of Texas MD Anderson Cancer Center. 2021.-URL: https://www.mdanderson.org/cancerwise/chemotherapy-at-home--9-things-to-know.h00-159464790.html.
Рекомендации MASCC для пациентов, получающих пероральные противоопухолевые препараты. Multinational Association of Supportive Care in Cancer (MASCC). 2023.-URL: https://mascc.org/wp-content/uploads/2023/09/moatt_russian_v1.2_Rev2.pdf.
[MASCC Teaching Tool for Patients Receiving Oral Agents for Cancer. Multinational Association of Supportive Care in Cancer (MASCC). 2023.-URL: https://mascc.org/wp-content/uploads/2023/09/moatt_russian_v1.2_Rev2.pdf. (In Rus)].
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2024